Related Experiment Videos
Valvular Heart Disease in the Pregnant Patient
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.
Current Treatment Options in Cardiovascular Medicine
|January 5, 2001
Summary
Managing anticoagulation in pregnant patients with valve disease is complex due to risks from both the condition and treatments. Evidence-based guidance is lacking, necessitating careful risk assessment and monitoring throughout pregnancy.
Area of Science:
- Cardiology
- Obstetrics
- Pharmacology
Background:
- Anticoagulation in pregnant patients with heart valve disease presents significant maternal and fetal risks.
- Current treatment guidelines lack robust evidence, relying on limited retrospective data.
- Existing anticoagulants like warfarin and unfractionated heparin have safety and efficacy concerns.
Purpose of the Study:
- To highlight the challenges in anticoagulation management for pregnant patients with valve disease.
- To underscore the need for evidence-based treatment strategies.
- To emphasize the importance of risk-benefit assessment and patient counseling.
Main Methods:
- Review of existing literature and clinical practice.
- Analysis of limitations in current treatment algorithms derived from registries and case series.
- Discussion of ethical and legal challenges in pregnant patient research.
Main Results:
- No randomized controlled trials exist to guide anticoagulation decisions in this population.
- Warfarin and unfractionated heparin demonstrate suboptimal efficacy and safety.
- Low molecular weight heparins (LMWHs) are increasingly used without sufficient evidence.
Conclusions:
- Anticoagulant management requires full disclosure of risks and limitations prior to conception.
- Treatment decisions must balance thrombosis and hemorrhage risks.
- Continuous monitoring and dosage adjustments are crucial throughout pregnancy, labor, and postpartum.